NUVB · Nuvation Bio Inc.
Nuvation Bio Inc (NUVB)
What's happening
- NUVB is down 1.29% today, trading at $6.86. — Live quote
- Volume today (5,181) is well below its 3-month average of 6,129,350. (Finnhub fundamentals)
- Last quarter's EPS beat estimates: $-0.15 actual vs. $-0.19 estimated (+20.6%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-09-01 (18 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $1.98B | $2.31B | $1.29B | $678.6M | $585.6M |
| P/E | -11.50 | -14.20 | -6.16 | -1.10 | -1.02 |
| Price/Sales | 14.91 | 22.15 | 59.20 | 67.33 | — |
| Price/Book | 7.80 | 7.23 | 3.95 | 1.82 | 1.40 |
| EV/Revenue | 14.84 | 21.46 | 57.08 | 47.94 | — |
| ROE | -67.85% | -50.89% | -64.21% | -165.17% | -136.30% |
| ROA | -23.14% | -26.65% | -34.78% | -95.17% | -116.09% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E and PEG aren't shown here — both need historical analyst-consensus estimates, which no free source provides; see the current-period figures above instead.
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-08-14. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Signals describe daily price patterns—not the company’s value and not a recommendation to buy or sell. Read several together; no single indicator predicts what happens next. “Overbought” and “oversold” are conditions, not promises of a reversal.
Indicators None active
Free IEX historical data only goes back to ~2021 — 5Y/Full show whatever's actually available, not a promise of that much history. Indicators are computed client-side from these same price bars; earnings markers ("E") come from Finnhub's free tier (~last 4 quarters + next upcoming) — older quarters aren't available. The move-highlight dots are a heuristic (|% change| vs rolling volatility) with a best-effort headline lookup, not a claim of causation.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 555.6% on the provider's reported measure. Finnhub fundamentals ↗
- Trailing 52-week price return is +120.0%. Finnhub market metrics ↗
Potential concerns
- Net profit margin is -88.2%. Finnhub fundamentals ↗
- Latest SEC filing is Form 4, filed 2026-08-21; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on NUVB
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $31.7M | $83.2M | $13.1M | $4.8M | $3.1M | $727.0K | $1.4M | — |
| Gross profit | — | — | $9.8M | $2.3M | $990.0K | -$788.0K | $88.0K | $0 |
| Operating income | -$51.0M | $3.9M | -$56.4M | -$63.6M | -$59.0M | -$48.1M | -$470.4M | -$20.2M |
| Net income | -$62.8M | $5.4M | -$55.8M | -$59.0M | -$53.2M | -$41.2M | -$462.5M | -$14.8M |
| EPS (diluted) | $-0.18 | $0.01 | $-0.16 | $-0.17 | $-0.16 | $-0.15 | $-1.89 | $-0.07 |
| EPS (basic) | $-0.18 | $0.02 | $-0.16 | $-0.17 | $-0.16 | $-0.15 | $-1.89 | $-0.07 |
| Operating margin | -$161 | $5 | -$430 | -$1.3K | -$1.9K | -$6.6K | -$32.8K | — |
| Net margin | -$198 | $6 | -$425 | -$1.2K | -$1.7K | -$5.7K | -$32.2K | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $744.5M | $610.2M | $594.8M | $601.6M | $647.2M | $492.5M | $540.6M | $571.6M |
| Total liabilities | $490.6M | $290.7M | $289.1M | $275.7M | $274.3M | $73.0M | $76.8M | $68.9M |
| Stockholders' equity | $253.9M | $319.6M | $305.7M | $325.9M | $372.9M | $419.5M | $463.8M | $502.7M |
| Total current assets | $726.4M | $591.5M | $571.5M | $577.5M | $623.2M | $475.6M | $526.3M | $565.0M |
| Total current liabilities | $86.8M | $79.5M | $82.2M | $68.1M | $66.4M | $52.8M | $58.2M | $59.0M |
| Cash & equivalents | $258.6M | $125.4M | $164.1M | $98.9M | $248.0M | $48.0M | $35.7M | $30.0M |
| Marketable securities (current) | $402.4M | $408.3M | $365.1M | $450.1M | $359.8M | $413.7M | $467.0M | $519.1M |
| Inventory | $19.9M | $15.8M | $11.4M | $5.7M | $552.0K | $14.0K | $0 | — |
| Property, plant & equipment | $715.0K | $535.0K | $564.0K | $560.0K | $615.0K | $562.0K | $586.0K | $719.0K |
| Intangible assets | $10.3M | $10.8M | $11.2M | $11.7M | $12.1M | $4.4M | $4.6M | $2.8M |
| Other non-current assets | $3.8M | $3.8M | $7.6M | $7.5M | $6.6M | $6.6M | $6.8M | $480.0K |
| Accounts payable | $12.1M | $22.4M | $9.5M | $15.4M | $22.4M | $10.5M | $6.3M | $12.4M |
| Accrued liabilities | $45.2M | $32.9M | $45.2M | $32.6M | $24.0M | $23.9M | $32.8M | $23.5M |
| Deferred revenue (current) | $8.9M | $8.7M | $7.5M | $6.7M | $9.7M | $10.8M | $11.1M | $12.9M |
| Short-term debt | $5.9M | $5.8M | $5.7M | $5.6M | $5.6M | $5.7M | $6.3M | $8.4M |
| Long-term debt | $242.6M | $47.3M | $47.2M | $47.1M | $47.0M | — | — | — |
| Common stock & paid-in capital | $1.43B | $1.43B | $1.42B | $1.40B | $1.40B | $1.38B | $1.37B | $1.36B |
| Retained earnings | -$1.17B | -$1.11B | -$1.12B | -$1.08B | -$1.02B | -$964.0M | -$910.7M | -$861.3M |
| Accumulated other comprehensive income (loss) | -$2.6M | -$1.7M | -$187.0K | -$139.0K | -$327.0K | $545.0K | $573.0K | $1.4M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$43.0M | $5.1M | -$29.7M | -$52.9M | -$48.2M | -$42.6M | -$46.3M | -$31.1M |
| Investing cash flow | $6.0M | -$43.6M | $87.1M | -$96.6M | $54.9M | $54.2M | $51.8M | $29.1M |
| Financing cash flow | $170.5M | $44.0K | $8.1M | $501.0K | $193.4M | $548.0K | -$900.0K | -$1.5M |
| Share-based compensation | $10.5M | $9.0M | $8.0M | $8.0M | $12.0M | $7.9M | $10.2M | $7.5M |
| Deferred income taxes | — | — | — | — | — | — | — | — |
| Change in accounts receivable | $5.1M | $6.6M | $7.8M | $5.6M | $2.3M | -$12.3M | $12.6M | -$5.0K |
| Change in accounts payable | -$9.8M | $13.0M | -$5.9M | -$7.1M | $11.9M | $4.2M | -$6.0M | $7.2M |
| Purchases of investments | $67.7M | $82.1M | $44.9M | $167.1M | $81.7M | $60.7M | $32.0M | $85.7M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $62.9M | $7.9M | — | — | — |
| Gross profit | — | $795.0K | $0 | — | — |
| Operating income | -$213.1M | -$592.6M | -$99.8M | -$119.7M | -$93.3M |
| Net income | -$204.6M | -$567.9M | -$75.8M | -$104.2M | -$86.8M |
| EPS (diluted) | $-0.60 | $-2.11 | $-0.35 | $-0.48 | $-0.44 |
| EPS (basic) | $-0.60 | $-2.11 | $-0.35 | $-0.48 | $-0.44 |
| Operating margin | -$339 | -$7.5K | — | — | — |
| Net margin | -$325 | -$7.2K | — | — | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $594.8M | $540.6M | $621.5M | $672.1M | $776.2M |
| Total liabilities | $289.1M | $76.8M | $16.4M | $17.1M | $30.2M |
| Stockholders' equity | $305.7M | $463.8M | $605.1M | $655.1M | $746.0M |
| Total current assets | $571.5M | $526.3M | $616.4M | $667.3M | $772.1M |
| Total current liabilities | $82.2M | $58.2M | $14.0M | $13.2M | $16.9M |
| Cash & equivalents | $164.1M | $35.7M | $42.6M | $101.1M | $132.4M |
| Marketable securities (current) | $365.1M | $467.0M | $568.6M | $559.9M | $633.0M |
| Inventory | $11.4M | $0 | — | — | — |
| Property, plant & equipment | $564.0K | $586.0K | $717.0K | $894.0K | $786.0K |
| Intangible assets | $11.2M | $4.6M | $0 | — | — |
| Other non-current assets | $7.6M | $6.8M | $587.0K | $0 | — |
| Accounts payable | $9.5M | $6.3M | $2.2M | $2.1M | $3.9M |
| Accrued liabilities | $45.2M | $32.8M | $9.8M | $9.8M | $12.1M |
| Deferred revenue (current) | $7.5M | $11.1M | $0 | — | — |
| Short-term debt | $5.7M | $6.3M | $0 | — | — |
| Long-term debt | $47.2M | — | — | — | — |
| Common stock & paid-in capital | $1.42B | $1.37B | $947.7M | $927.6M | $910.0M |
| Retained earnings | -$1.12B | -$910.7M | -$342.8M | -$267.0M | -$162.8M |
| Accumulated other comprehensive income (loss) | -$187.0K | $573.0K | $181.0K | -$5.5M | -$1.2M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$173.4M | -$130.4M | -$68.0M | -$96.1M | -$68.2M |
| Investing cash flow | $99.5M | $122.7M | $8.9M | $63.5M | -$454.7M |
| Financing cash flow | $202.5M | $331.0K | $628.0K | $1.3M | $625.5M |
| Share-based compensation | $35.9M | $32.3M | $19.5M | $16.3M | $9.3M |
| Deferred income taxes | — | — | — | $0 | $0 |
| Change in accounts receivable | $3.4M | $12.7M | $0 | — | — |
| Change in accounts payable | $3.1M | -$1.7M | $70.0K | -$1.8M | $1.9M |
| Purchases of investments | $354.4M | $339.6M | $703.4M | $520.3M | $609.3M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding NUVB as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-02-27 to 2026-08-19
Recent transactions
- Insiders have net sold 597,418 shares over the last 182 days, across 1 purchase and 7 sales.
- Most recent: Hattersley Gary (CHIEF SCIENTIFIC OFFICER) — Option exercise of 100,000 shares on 2026-08-19.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Hattersley Gary | CHIEF SCIENTIFIC OFFICER | Option exercise | 2026-08-19 | 100,000 |
| Sauvage Philippe | Chief Financial Officer | Option exercise | 2026-07-15 | 39,999 |
| Markel Stacy | CHIEF PEOPLE OFFICER | Option exercise | 2026-06-23 | 90,380 |
| Wentworth Kerry | CHIEF REGULATORY OFFICER | Option exercise | 2026-06-23 | 63,000 |
| Mashal Robert | Reporting person | Open market purchase | 2026-06-09 | 25,000 |
| Liu Dongfang | CHIEF MEDICAL OFFICER | Option exercise | 2026-04-17 | 50,000 |
| Makunje Moses | SEE REMARKS | Grant / award | 2026-02-27 | 50,761 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-19 | Hattersley Gary | CHIEF SCIENTIFIC OFFICER | Option exercise | 100,000 | $1.87 |
| 2026-08-19 | Hattersley Gary | CHIEF SCIENTIFIC OFFICER | Open market sale | 100,000 | $7.09 |
| 2026-07-15 | Sauvage Philippe | Chief Financial Officer | Option exercise | 39,999 | $2.17 |
| 2026-07-15 | Sauvage Philippe | Chief Financial Officer | Option exercise | 1 | $1.97 |
| 2026-06-23 | Markel Stacy | CHIEF PEOPLE OFFICER | Option exercise | 90,380 | $1.87 |
| 2026-06-23 | Markel Stacy | CHIEF PEOPLE OFFICER | Option exercise | 34,620 | $1.74 |
| 2026-06-23 | Markel Stacy | CHIEF PEOPLE OFFICER | Open market sale | 125,000 | $6.03 |
| 2026-06-23 | Wentworth Kerry | CHIEF REGULATORY OFFICER | Option exercise | 63,000 | $2.93 |
| 2026-06-23 | Wentworth Kerry | CHIEF REGULATORY OFFICER | Open market sale | 63,000 | $6.02 |
| 2026-06-23 | Sauvage Philippe | Chief Financial Officer | Option exercise | 47,668 | $2.17 |
| 2026-06-23 | Sauvage Philippe | Chief Financial Officer | Open market sale | 47,668 | $6.01 |
| 2026-06-09 | Mashal Robert | Reporting person | Open market purchase | 25,000 | $4.73 |
| 2026-04-17 | Wentworth Kerry | CHIEF REGULATORY OFFICER | Option exercise | 36,750 | $2.93 |
| 2026-04-17 | Wentworth Kerry | CHIEF REGULATORY OFFICER | Open market sale | 36,750 | $5.01 |
| 2026-04-17 | Liu Dongfang | CHIEF MEDICAL OFFICER | Option exercise | 50,000 | $1.94 |
| 2026-04-17 | Liu Dongfang | CHIEF MEDICAL OFFICER | Open market sale | 50,000 | $5.02 |
| 2026-04-06 | Wentworth Kerry | CHIEF REGULATORY OFFICER | Option exercise | 100,000 | $1.87 |
| 2026-04-06 | Wentworth Kerry | CHIEF REGULATORY OFFICER | Option exercise | 100,000 | $1.94 |
| 2026-04-06 | Wentworth Kerry | CHIEF REGULATORY OFFICER | Open market sale | 200,000 | $4.52 |
| 2026-02-27 | Makunje Moses | SEE REMARKS | Grant / award | 50,761 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-09-03 13:46 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-21 | 4 | 2026-08-19 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-07-17 | 4 | 2026-07-15 | View on SEC.gov → |
| 2026-07-06 | 8-K | 2026-06-30 | View on SEC.gov → |
| 2026-06-30 | 8-K | 2026-06-24 | View on SEC.gov → |
| 2026-06-24 | 4 | 2026-06-23 | View on SEC.gov → |
| 2026-06-24 | 4 | 2026-06-23 | View on SEC.gov → |
| 2026-06-24 | 4 | 2026-06-23 | View on SEC.gov → |
| 2026-06-11 | 4 | 2026-06-09 | View on SEC.gov → |
| 2026-05-27 | 8-K | 2026-05-21 | View on SEC.gov → |
| 2026-05-26 | 4 | 2026-05-21 | View on SEC.gov → |
Recent news
Headlines about NUVB (Nuvation Bio Inc.). Links open the publisher — we don’t host full articles.
-
Nuvation Bio to Participate in Upcoming Investor Conferences
Yahoo Finance · 2026-09-02 -
Nuvation Bio (NUVB) Upgraded to Buy: Here's Why
Yahoo Finance · 2026-08-31 -
Nuvation: Why I'm Downgrading To Hold Despite Progress On NSCLC And Glioma Fronts
SeekingAlpha · 2026-08-26 -
Nuvation Bio rises as Cantor initiates at overweight
Seeking Alpha · 2026-08-21 -
Cantor Fitzgerald Initiates Coverage of Nuvation Bio (NUVB) with Overweight Recommendation
Fintel · 2026-08-21 -
This Teradyne Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Benzinga · 2026-08-21 -
This Equifax Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Benzinga · 2026-08-21 -
This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Benzinga · 2026-08-21
No headlines in this category right now — try “All”.